Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Enzon To Spin Off Biotech Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

Enzon To Spin Off Biotech Business

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon Pharmaceuticals, Inc. announced plans to spin off its biotechnology business into an independent company focusing on the development of cancer treatments. Enzon will fund the new company with $150 million, which is expected to provide two to three years of R&D activity. The transaction, which is subject to approval from Enzon’s board of directors, is expected to close in the fourth quarter.
   
Jeffrey H. Buchalter, Enzon’s chief executive officer, will head the new company and Enzon’s current chief financial officer, Craig Tooman will be responsible for the specialty pharmaceuticals business. Each company will have separate management teams.
   
“By separating these unique businesses into two focused companies, the opportunities for both the specialty pharmaceutical business and the biotechnology business could be substantially enhanced and greater value could be created than under the current structure,” said Mr. Buchalter.
   
Enzon will also retain rights to its currently marketed drugs, which include Oncaspar for leukemia, Depocyt for meningitis, Abelcet for fungal infections and Adagen for severe combined immunodeficiency disease. In addition, it will retain rights to its royalty revenues.
   
The company also recently reported 1Q08 results. Revenues were $48.8 million (+18%). Earnings were $1.5 million compared to a loss of $2.8 million in 1Q07.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters